<DOC>
	<DOCNO>NCT00053300</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth cancer stop blood flow tumor . PURPOSE : Phase II trial study effectiveness thalidomide treat patient extensive-stage small cell lung cancer respond previous chemotherapy .</brief_summary>
	<brief_title>Thalidomide Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect thalidomide time disease progression survival patient extensive-stage small cell lung cancer achieve complete partial response induction chemotherapy . - Determine toxicity drug patient . OUTLINE : This open-label study . Patients receive oral thalidomide daily begin 3-4 week completion induction chemotherapy . Treatment continue 1 year absence disease progression unacceptable toxicity Patients follow every 3 month . PROJECTED ACCRUAL : A total 30 patient accrue study within approximately 18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis extensivestage small cell lung cancer Complete partial response 46 course induction chemotherapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 2 month Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use 2 effective method contraception least 4 week , , least 4 week study No great grade 1 peripheral neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>